Loading...
Loading...
SPRY| Name | Value |
|---|---|
| Revenues | 2.1M |
| Cost of Revenue | 0.1M |
| Gross Profit | 2.0M |
| Operating Expense | 23.7M |
| Operating I/L | -21.7M |
| Other Income/Expense | 2.6M |
| Interest Income | 0.0M |
| Pretax | -19.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -19.1M |
ARS Pharmaceuticals, Inc. specializes in developing ARS-1, an innovative intranasal epinephrine spray designed for individuals and families at risk of severe allergic reactions to food, medications, and insect bites. Their flagship product, Neffy, is a low-dose intranasal epinephrine nasal spray. The company generates revenue by selling these life-saving medical products to consumers and healthcare providers, addressing the critical need for effective and convenient treatment options for severe allergic reactions.
